Management of Low Factor D with Hemoglobinuria but No Overt TMA
Despite the absence of classic TMA markers (schistocytes, MAHA), the combination of low Factor D, persistent hemoglobinuria, mild LDH elevation, and low-grade AKI strongly suggests subclinical complement-mediated TMA (cmTMA/aHUS), and you should proceed with comprehensive complement workup and consider early complement inhibition therapy while monitoring closely for disease progression. 1
Clinical Reasoning
Why This Is Likely Complement-Mediated TMA Despite Negative Classic Markers
The 2025 Italian multidisciplinary consensus explicitly addresses your exact scenario:
- Absence of schistocytes does not exclude TMA diagnosis 1. The guidelines emphasize that schistocyte testing has low sensitivity, and their absence should not prevent earlier TMA diagnosis 1
- Not all three classic signs (hemolysis, thrombocytopenia, renal involvement) are clearly present in almost 50% of cases at onset 1
- Low Factor D specifically indicates alternative complement pathway dysregulation, which is the hallmark of cmTMA/aHUS
Multiple case reports confirm TMA can occur without peripheral blood schistocytes 2, 3. In severe cases, schistocytes may be absent due to increased endothelial permeability 3, and the degree of hemolysis may be too low to produce detectable fragmented cells 2.
The Hemoglobinuria Without Overt Hemolysis Paradox
Your patient's persistent hemoglobinuria with normal hemolysis markers (except mild LDH elevation) represents intravascular hemolysis at a subclinical level. This pattern, combined with low Factor D, suggests:
- Ongoing complement-mediated endothelial injury
- Sufficient red cell destruction to produce hemoglobinuria but below the threshold for dramatic LDH elevation or schistocyte formation
- Early or smoldering disease that may rapidly progress
Immediate Next Steps
1. Complete Second-Level Complement Testing (Urgent)
Beyond Factor D, obtain 1:
- C3, C4 levels
- CH50 and AP50 (alternative pathway activity)
- Factor H, Factor I levels
- Anti-Factor H antibodies
- Genetic testing for complement regulatory genes (CFH, CFI, MCP/CD46, CFB, C3, THBD, DGKE)
2. Rule Out Other TMA Causes
- ADAMTS13 activity - Must be <10 IU/dL to diagnose TTP 1, 4. If >10 IU/dL, supports cmTMA diagnosis
- Stool for Shiga toxin/STEC - Rule out typical HUS 1
- Exclude secondary causes: autoimmune markers (ANA, ANCA, anti-dsDNA), pregnancy status, malignancy, drug exposures 1
3. Kidney Biopsy Interpretation
Your statement that "biopsy was clear" needs reconsideration. Request specific re-review for TMA features:
- Arteriolar and capillary thrombi
- Endothelial swelling
- Mesangiolysis
- Glomerular basement membrane duplication
TMA can be patchy and easily missed on routine examination 3.
Treatment Decision Algorithm
If Complement Testing Confirms Dysregulation (Low C3, Low Factor D, Positive Genetic Mutations or Anti-Factor H Antibodies):
Initiate complement inhibition therapy immediately 1, 4:
- Eculizumab (C5 inhibitor) or Ravulizumab (longer-acting C5 inhibitor)
- Both are FDA-approved for cmTMA/aHUS
- Treatment should begin within 4-8 hours of diagnosis, as delays increase morbidity and mortality 1
Before starting C5 inhibition 1:
- Administer quadrivalent meningococcal conjugate vaccine (A, C, W, Y)
- Administer meningococcal B vaccine
- Start prophylactic penicillin (or macrolide if allergic) for duration of therapy
If ADAMTS13 <10 IU/dL (Unlikely Given Your Presentation):
- Immediate plasmapheresis
- Add caplacizumab (anti-vWF antibody)
If All Testing Returns Normal:
- Do not dismiss the diagnosis - genetic mutations are found in only 50-60% of cmTMA cases
- Consider empiric complement inhibition trial if clinical suspicion remains high
- Monitor intensively for progression
Critical Monitoring Parameters
Track these markers at least every 48-72 hours initially:
- Hemoglobin/hematocrit - Watch for worsening anemia
- Platelet count - May drop as disease progresses
- LDH - Trending upward suggests worsening hemolysis
- Haptoglobin - Will decrease with increased hemolysis
- Creatinine - Monitor renal function closely
- Urine hemoglobin - Persistence indicates ongoing process
- Peripheral smear - Schistocytes may appear later in disease course
Common Pitfalls to Avoid
Waiting for "classic" TMA triad - By the time all three features appear, irreversible organ damage may have occurred 1
Dismissing diagnosis due to negative biopsy - TMA can be focal and sampling-dependent 3
Assuming normal hemolysis markers exclude TMA - Low-grade or early disease may not produce dramatic laboratory abnormalities 2
Delaying treatment pending genetic results - Genetic testing takes weeks; clinical decision must be made based on available data 1
Confusing absence of schistocytes with absence of disease - This is explicitly warned against in current guidelines 1
Prognosis and Long-Term Considerations
- Untreated cmTMA has 25% mortality and 50% progress to end-stage renal disease
- Early complement inhibition dramatically improves outcomes
- Treatment duration is typically lifelong, though some patients with identified triggers (infection, pregnancy) may discontinue after extended remission
- Genetic counseling is recommended for patients and family members once results available
The constellation of low Factor D, persistent hemoglobinuria, and mild renal dysfunction represents a red flag for evolving complement-mediated disease that warrants aggressive investigation and low threshold for therapeutic intervention 1, 4.